| Name | Title | Contact Details |
|---|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilenâ„¢ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilenâ„¢ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
Fifty 50 Pharmacy is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Texas Road Pharmacy is a Monroe Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Scientia Vascular offers access devices (microcatheters / guidewires) and therapies that are optimized to address the evolving needs of interventional specialists. Learn more about our next-generation solutions.
Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. Endo`s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,400 people worldwide*.